English

Abraxis BioScience, Inc.

EDGAR

Quarterly report (10-Q) · filed 2010-08-05

17 filing records in this dataset, filed from 2007-12-20 to 2010-08-05. Explore the available filing history and original sources.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

135 million USD

2010-06-30 · USD

Exact inputs and evidence

Revenue: 135295000 USD Source

Operating margin

-15.34%

2010-06-30 · %

Exact inputs and evidence

Operating Income: -20751000 USD Source
Revenue: 135295000 USD Source

Operating cash flow

-2.49 million USD

2010-06-30 · USD

Exact inputs and evidence

Operating Cash Flow: 3231000 USD Source
Operating Cash Flow: 5723000 USD Source

Free cash flow

-22.1 million USD

2010-06-30 · USD

Exact inputs and evidence

Operating Cash Flow: 3231000 USD Source
Operating Cash Flow: 5723000 USD Source
Capital Expenditure: 34918000 USD Source
Capital Expenditure: 15331000 USD Source

Cash and cash equivalents: 172 million USD 2010-06-30 Source
Exact value

171724000 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

447 million USD

2009-07-01 – 2010-06-30

Exact inputs and evidence

Revenue: 96628000 USD · 2009-07-01 – 2009-09-30 Source
Revenue: 359050000 USD · 2009-01-01 – 2009-12-31 Source
Revenue: 254339000 USD · 2009-01-01 – 2009-09-30 Source
Revenue: 110830000 USD · 2010-01-01 – 2010-03-31 Source
Revenue: 135295000 USD · 2010-04-01 – 2010-06-30 Source

Net income

-75.6 million USD

2009-07-01 – 2010-06-30

Exact inputs and evidence

Net income: -37714000 USD · 2009-07-01 – 2009-09-30 Source
Net income: -103116000 USD · 2009-01-01 – 2009-12-31 Source
Net income: -84068000 USD · 2009-01-01 – 2009-09-30 Source
Net income: -3003000 USD · 2010-01-01 – 2010-03-31 Source
Net income: -15860000 USD · 2010-04-01 – 2010-06-30 Source

Operating cash flow

-7.3 million USD

2009-07-01 – 2010-06-30

Exact inputs and evidence

Operating cash flow: -29106000 USD · 2009-01-01 – 2009-09-30 Source
Operating cash flow: 15016000 USD · 2009-01-01 – 2009-06-30 Source
Operating cash flow: 4488000 USD · 2009-01-01 – 2009-12-31 Source
Operating cash flow: -29106000 USD · 2009-01-01 – 2009-09-30 Source
Operating cash flow: 5723000 USD · 2010-01-01 – 2010-03-31 Source
Operating cash flow: 3231000 USD · 2010-01-01 – 2010-06-30 Source
Operating cash flow: 5723000 USD · 2010-01-01 – 2010-03-31 Source

Capital expenditure

61 million USD

2009-07-01 – 2010-06-30

Exact inputs and evidence

Capital expenditure: 86716000 USD · 2009-01-01 – 2009-09-30 Source
Capital expenditure: 68382000 USD · 2009-01-01 – 2009-06-30 Source
Capital expenditure: 94473000 USD · 2009-01-01 – 2009-12-31 Source
Capital expenditure: 86716000 USD · 2009-01-01 – 2009-09-30 Source
Capital expenditure: 15331000 USD · 2010-01-01 – 2010-03-31 Source
Capital expenditure: 34918000 USD · 2010-01-01 – 2010-06-30 Source
Capital expenditure: 15331000 USD · 2010-01-01 – 2010-03-31 Source

Free cash flow

-68.3 million USD

2009-07-01 – 2010-06-30

Exact inputs and evidence

Operating cash flow: -29106000 USD · 2009-01-01 – 2009-09-30 Source
Operating cash flow: 15016000 USD · 2009-01-01 – 2009-06-30 Source
Operating cash flow: 4488000 USD · 2009-01-01 – 2009-12-31 Source
Operating cash flow: -29106000 USD · 2009-01-01 – 2009-09-30 Source
Operating cash flow: 5723000 USD · 2010-01-01 – 2010-03-31 Source
Operating cash flow: 3231000 USD · 2010-01-01 – 2010-06-30 Source
Operating cash flow: 5723000 USD · 2010-01-01 – 2010-03-31 Source
Capital expenditure: 86716000 USD · 2009-01-01 – 2009-09-30 Source
Capital expenditure: 68382000 USD · 2009-01-01 – 2009-06-30 Source
Capital expenditure: 94473000 USD · 2009-01-01 – 2009-12-31 Source
Capital expenditure: 86716000 USD · 2009-01-01 – 2009-09-30 Source
Capital expenditure: 15331000 USD · 2010-01-01 – 2010-03-31 Source
Capital expenditure: 34918000 USD · 2010-01-01 – 2010-06-30 Source
Capital expenditure: 15331000 USD · 2010-01-01 – 2010-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2010-08-05.

Financial data available through: 2009-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2009-12-31
Operating income: 5 of 11 periods available· newest 2009-12-31
Net income: 5 of 11 periods available· newest 2009-12-31
Operating cash flow: 5 of 11 periods available· newest 2009-12-31
Capital expenditure: 5 of 11 periods available· newest 2009-12-31
Total assets: 4 of 11 periods available· newest 2009-12-31
Total liabilities: 4 of 11 periods available· newest 2009-12-31
Current assets: 4 of 11 periods available· newest 2009-12-31
Current liabilities: 4 of 11 periods available· newest 2009-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2009-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+4%

Prior period

USD 345.31 million

2008-01-01 – 2008-12-31
Current period

USD 359.05 million

2009-01-01 – 2009-12-31

Exact inputs and evidence

359050000 − 345309000 = 13741000 USD

345309000 USD · 2008-01-01 – 2008-12-31
Inspect prior input Prior source
359050000 USD · 2009-01-01 – 2009-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Abraxis BioScience, Inc. · 2009-12-31 Abraxis BioScience, Inc. (edgar:1409012) Year-over-year change in Revenue: 13741000 USD Concept: fundies:Revenue Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 359050000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#6593 Input fundies:Revenue: 345309000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#6593
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 173.66 million

Prior period

−USD 276.77 million

2008-01-01 – 2008-12-31
Current period

−USD 103.12 million

2009-01-01 – 2009-12-31

Exact inputs and evidence

-103116000 − -276771000 = 173655000 USD

-276771000 USD · 2008-01-01 – 2008-12-31
Inspect prior input Prior source
-103116000 USD · 2009-01-01 – 2009-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Abraxis BioScience, Inc. · 2009-12-31 Abraxis BioScience, Inc. (edgar:1409012) Year-over-year change in Net income: 173655000 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -103116000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#6971 Input fundies:NetIncome: -276771000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#6971
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 319.96 million

Prior period

−USD 315.47 million

2008-01-01 – 2008-12-31
Current period

USD 4.49 million

2009-01-01 – 2009-12-31

Exact inputs and evidence

4488000 − -315468000 = 319956000 USD

-315468000 USD · 2008-01-01 – 2008-12-31
Inspect prior input Prior source
4488000 USD · 2009-01-01 – 2009-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Abraxis BioScience, Inc. · 2009-12-31 Abraxis BioScience, Inc. (edgar:1409012) Year-over-year change in Operating cash flow: 319956000 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 4488000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#8961 Input fundies:OperatingCashFlow: -315468000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#8961
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+116%

Prior period

USD 43.73 million

2008-01-01 – 2008-12-31
Current period

USD 94.47 million

2009-01-01 – 2009-12-31

Exact inputs and evidence

94473000 − 43729000 = 50744000 USD

43729000 USD · 2008-01-01 – 2008-12-31
Inspect prior input Prior source
94473000 USD · 2009-01-01 – 2009-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Abraxis BioScience, Inc. · 2009-12-31 Abraxis BioScience, Inc. (edgar:1409012) Year-over-year change in Capital expenditure: 50744000 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 94473000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#9003 Input fundies:CapitalExpenditure: 43729000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#9003
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2009 2009-01-01 – 2009-12-31

Revenue USD 359.05 million 100% of revenue
Operating costs Derived USD 472.8 million 132% of revenue
Operating income −USD 113.75 million −32% of revenue
Tax, interest and other Derived −USD 10.63 million −3% of revenue
Net income −USD 103.12 million −29% of revenue

Cash

Operating cash flow USD 4.49 million 1.2% of revenue
Capital expenditure USD 94.47 million 26% of revenue
Free cash flow Derived −USD 89.99 million −25% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2005 Operating loss: operating costs were 104% of revenue.
2006 Operating loss: operating costs were 180% of revenue.
2007 Operating loss: operating costs were 117% of revenue.
2008 Operating loss: operating costs were 185% of revenue.
2009 Operating loss: operating costs were 132% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2005 2005-01-01 – 2005-12-31	135675000	141583000 Derived	-5908000	6754000 Derived	-12662000	-39484000 Derived	Source 2005-01-01 – 2005-12-31: 135675000 USD Inspect Revenue Open source 2005-01-01 – 2005-12-31: -5908000 USD Inspect Operating Income Open source 2005-01-01 – 2005-12-31: -12662000 USD Inspect Net Income Open source 2005-01-01 – 2005-12-31: -22272000 USD Inspect Operating Cash Flow Open source 2005-01-01 – 2005-12-31: 17212000 USD Inspect Capital Expenditure Open source
2006 2006-01-01 – 2006-12-31	182287000	328460000 Derived	-146173000	-21622000 Derived	-124551000	106439000 Derived	Source 2006-01-01 – 2006-12-31: 182287000 USD Inspect Revenue Open source 2006-01-01 – 2006-12-31: -146173000 USD Inspect Operating Income Open source 2006-01-01 – 2006-12-31: -124551000 USD Inspect Net Income Open source 2006-01-01 – 2006-12-31: 170870000 USD Inspect Operating Cash Flow Open source 2006-01-01 – 2006-12-31: 64431000 USD Inspect Capital Expenditure Open source
2007 2007-01-01 – 2007-12-31	333686000	391813000 Derived	-58127000	-16523000 Derived	-41604000	-43474000 Derived	Source 2007-01-01 – 2007-12-31: 333686000 USD Inspect Revenue Open source 2007-01-01 – 2007-12-31: -58127000 USD Inspect Operating Income Open source 2007-01-01 – 2007-12-31: -41604000 USD Inspect Net Income Open source 2007-01-01 – 2007-12-31: -2893000 USD Inspect Operating Cash Flow Open source 2007-01-01 – 2007-12-31: 40581000 USD Inspect Capital Expenditure Open source
2008 2008-01-01 – 2008-12-31	345309000	638549000 Derived	-293240000	-16469000 Derived	-276771000	-359197000 Derived	Source 2008-01-01 – 2008-12-31: 345309000 USD Inspect Revenue Open source 2008-01-01 – 2008-12-31: -293240000 USD Inspect Operating Income Open source 2008-01-01 – 2008-12-31: -276771000 USD Inspect Net Income Open source 2008-01-01 – 2008-12-31: -315468000 USD Inspect Operating Cash Flow Open source 2008-01-01 – 2008-12-31: 43729000 USD Inspect Capital Expenditure Open source
2009 2009-01-01 – 2009-12-31	359050000	472795000 Derived	-113745000	-10629000 Derived	-103116000	-89985000 Derived	Source 2009-01-01 – 2009-12-31: 359050000 USD Inspect Revenue Open source 2009-01-01 – 2009-12-31: -113745000 USD Inspect Operating Income Open source 2009-01-01 – 2009-12-31: -103116000 USD Inspect Net Income Open source 2009-01-01 – 2009-12-31: 4488000 USD Inspect Operating Cash Flow Open source 2009-01-01 – 2009-12-31: 94473000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 359.1M 2009

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20052005-12-31	Revenue	135675000	Revenue: 135675000 Open source
20062006-12-31	Revenue	182287000	Revenue: 182287000 Open source
20072007-12-31	Revenue	333686000	Revenue: 333686000 Open source
20082008-12-31	Revenue	345309000	Revenue: 345309000 Open source
20092009-12-31	Revenue	359050000	Revenue: 359050000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

4% 2009

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20052005-12-31	Year over year	No prior comparable period	Revenue: 135675000 Open source
20062006-12-31	Year over year	34.4%	Revenue: 182287000 Open source Revenue: 135675000 Open source
20072007-12-31	Year over year	83.1%	Revenue: 333686000 Open source Revenue: 182287000 Open source
20082008-12-31	Year over year	3.5%	Revenue: 345309000 Open source Revenue: 333686000 Open source
20092009-12-31	Year over year	4%	Revenue: 359050000 Open source Revenue: 345309000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -31.7% 2009

Net margin -28.7% 2009

Free cash flow margin -25.1% 2009

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20052005-12-31	Operating margin	-4.4%	Operating Income: -5908000 Open source Revenue: 135675000 Open source
20062006-12-31	Operating margin	-80.2%	Operating Income: -146173000 Open source Revenue: 182287000 Open source
20072007-12-31	Operating margin	-17.4%	Operating Income: -58127000 Open source Revenue: 333686000 Open source
20082008-12-31	Operating margin	-84.9%	Operating Income: -293240000 Open source Revenue: 345309000 Open source
20092009-12-31	Operating margin	-31.7%	Operating Income: -113745000 Open source Revenue: 359050000 Open source
20052005-12-31	Net margin	-9.3%	Net Income: -12662000 Open source Revenue: 135675000 Open source
20062006-12-31	Net margin	-68.3%	Net Income: -124551000 Open source Revenue: 182287000 Open source
20072007-12-31	Net margin	-12.5%	Net Income: -41604000 Open source Revenue: 333686000 Open source
20082008-12-31	Net margin	-80.2%	Net Income: -276771000 Open source Revenue: 345309000 Open source
20092009-12-31	Net margin	-28.7%	Net Income: -103116000 Open source Revenue: 359050000 Open source
20052005-12-31	Free cash flow margin	-29.1%	Revenue: 135675000 Open source Operating Cash Flow: -22272000 Open source Capital Expenditure: 17212000 Open source
20062006-12-31	Free cash flow margin	58.4%	Revenue: 182287000 Open source Operating Cash Flow: 170870000 Open source Capital Expenditure: 64431000 Open source
20072007-12-31	Free cash flow margin	-13%	Revenue: 333686000 Open source Operating Cash Flow: -2893000 Open source Capital Expenditure: 40581000 Open source
20082008-12-31	Free cash flow margin	-104%	Revenue: 345309000 Open source Operating Cash Flow: -315468000 Open source Capital Expenditure: 43729000 Open source
20092009-12-31	Free cash flow margin	-25.1%	Revenue: 359050000 Open source Operating Cash Flow: 4488000 Open source Capital Expenditure: 94473000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 4.5M 2009

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20052005-12-31	Operating cash flow	-22272000	Operating Cash Flow: -22272000 Open source
20062006-12-31	Operating cash flow	170870000	Operating Cash Flow: 170870000 Open source
20072007-12-31	Operating cash flow	-2893000	Operating Cash Flow: -2893000 Open source
20082008-12-31	Operating cash flow	-315468000	Operating Cash Flow: -315468000 Open source
20092009-12-31	Operating cash flow	4488000	Operating Cash Flow: 4488000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -90M 2009

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20052005-12-31	Free cash flow	-39484000	Operating Cash Flow: -22272000 Open source Capital Expenditure: 17212000 Open source
20062006-12-31	Free cash flow	106439000	Operating Cash Flow: 170870000 Open source Capital Expenditure: 64431000 Open source
20072007-12-31	Free cash flow	-43474000	Operating Cash Flow: -2893000 Open source Capital Expenditure: 40581000 Open source
20082008-12-31	Free cash flow	-359197000	Operating Cash Flow: -315468000 Open source Capital Expenditure: 43729000 Open source
20092009-12-31	Free cash flow	-89985000	Operating Cash Flow: 4488000 Open source Capital Expenditure: 94473000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

20.8% 2009

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2005-12-31	Liabilities / assets	Not reported	No source recorded
20062006-12-31	Liabilities / assets	40%	Total Liabilities: 305762000 Open source Total Assets: 764783000 Open source
20072007-12-31	Liabilities / assets	20.3%	Total Liabilities: 304868000 Open source Total Assets: 1502255000 Open source
20082008-12-31	Liabilities / assets	33.6%	Total Liabilities: 470285000 Open source Total Assets: 1399757000 Open source
20092009-12-31	Liabilities / assets	20.8%	Total Liabilities: 222115000 Open source Total Assets: 1068380000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.08× 2009

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2005-12-31	Current assets / current liabilities	Not reported	No source recorded
20062006-12-31	Current assets / current liabilities	1.22×	Current Assets: 136826000 Open source Current Liabilities: 111733000 Open source
20072007-12-31	Current assets / current liabilities	6.18×	Current Assets: 876972000 Open source Current Liabilities: 141791000 Open source
20082008-12-31	Current assets / current liabilities	1.82×	Current Assets: 770006000 Open source Current Liabilities: 422685000 Open source
20092009-12-31	Current assets / current liabilities	2.08×	Current Assets: 371296000 Open source Current Liabilities: 178549000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2005 2005-01-01 – 2005-12-31	−USD 12.66 million Exact value Exact value: -12662000 USD 2005-01-01 – 2005-12-31: -12662000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Abraxis BioScience, Inc. · 2005-12-31 Abraxis BioScience, Inc. (edgar:1409012) Net Income: -12662000 USD Concept: fundies:NetIncome Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3ANetIncome&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12662000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-08-071377.txt#7286 The citation records this snapshot. The page link may show a newer release later.	−USD 22.27 million Exact value Exact value: -22272000 USD 2005-01-01 – 2005-12-31: -22272000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Abraxis BioScience, Inc. · 2005-12-31 Abraxis BioScience, Inc. (edgar:1409012) Operating Cash Flow: -22272000 USD Concept: fundies:OperatingCashFlow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3AOperatingCashFlow&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22272000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-08-071377.txt#7594 The citation records this snapshot. The page link may show a newer release later.	USD 17.21 million Exact value Exact value: 17212000 USD 2005-01-01 – 2005-12-31: 17212000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Abraxis BioScience, Inc. · 2005-12-31 Abraxis BioScience, Inc. (edgar:1409012) Capital Expenditure: 17212000 USD Concept: fundies:CapitalExpenditure Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3ACapitalExpenditure&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17212000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-08-071377.txt#7622 The citation records this snapshot. The page link may show a newer release later.	−USD 39.48 million Calculation and evidence -22272000 − 17212000 USD Exact free cash flow: -39484000 USD 2005-01-01 – 2005-12-31: -22272000 USD · Inspect Operating Cash Flow · Source 2005-01-01 – 2005-12-31: 17212000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Abraxis BioScience, Inc. · 2005-12-31 Abraxis BioScience, Inc. (edgar:1409012) Free cash flow: -39484000 USD Concept: free-cash-flow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22272000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-08-071377.txt#7594 Input fundies:CapitalExpenditure: 17212000 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-08-071377.txt#7622 The citation records this snapshot. The page link may show a newer release later.
2006 2006-01-01 – 2006-12-31	−USD 124.55 million Exact value Exact value: -124551000 USD 2006-01-01 – 2006-12-31: -124551000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Abraxis BioScience, Inc. · 2006-12-31 Abraxis BioScience, Inc. (edgar:1409012) Net Income: -124551000 USD Concept: fundies:NetIncome Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3ANetIncome&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:NetIncome: -124551000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-09-047452.txt#7801 The citation records this snapshot. The page link may show a newer release later.	USD 170.87 million Exact value Exact value: 170870000 USD 2006-01-01 – 2006-12-31: 170870000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Abraxis BioScience, Inc. · 2006-12-31 Abraxis BioScience, Inc. (edgar:1409012) Operating Cash Flow: 170870000 USD Concept: fundies:OperatingCashFlow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3AOperatingCashFlow&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 170870000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-09-047452.txt#8165 The citation records this snapshot. The page link may show a newer release later.	USD 64.43 million Exact value Exact value: 64431000 USD 2006-01-01 – 2006-12-31: 64431000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Abraxis BioScience, Inc. · 2006-12-31 Abraxis BioScience, Inc. (edgar:1409012) Capital Expenditure: 64431000 USD Concept: fundies:CapitalExpenditure Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3ACapitalExpenditure&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 64431000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-09-047452.txt#8193 The citation records this snapshot. The page link may show a newer release later.	USD 106.44 million Calculation and evidence 170870000 − 64431000 USD Exact free cash flow: 106439000 USD 2006-01-01 – 2006-12-31: 170870000 USD · Inspect Operating Cash Flow · Source 2006-01-01 – 2006-12-31: 64431000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Abraxis BioScience, Inc. · 2006-12-31 Abraxis BioScience, Inc. (edgar:1409012) Free cash flow: 106439000 USD Concept: free-cash-flow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 170870000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-09-047452.txt#8165 Input fundies:CapitalExpenditure: 64431000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-09-047452.txt#8193 The citation records this snapshot. The page link may show a newer release later.
2007 2007-01-01 – 2007-12-31	−USD 41.6 million Exact value Exact value: -41604000 USD 2007-01-01 – 2007-12-31: -41604000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Abraxis BioScience, Inc. · 2007-12-31 Abraxis BioScience, Inc. (edgar:1409012) Net Income: -41604000 USD Concept: fundies:NetIncome Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3ANetIncome&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41604000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#6971 The citation records this snapshot. The page link may show a newer release later.	−USD 2.89 million Exact value Exact value: -2893000 USD 2007-01-01 – 2007-12-31: -2893000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Abraxis BioScience, Inc. · 2007-12-31 Abraxis BioScience, Inc. (edgar:1409012) Operating Cash Flow: -2893000 USD Concept: fundies:OperatingCashFlow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3AOperatingCashFlow&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2893000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#8961 The citation records this snapshot. The page link may show a newer release later.	USD 40.58 million Exact value Exact value: 40581000 USD 2007-01-01 – 2007-12-31: 40581000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Abraxis BioScience, Inc. · 2007-12-31 Abraxis BioScience, Inc. (edgar:1409012) Capital Expenditure: 40581000 USD Concept: fundies:CapitalExpenditure Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3ACapitalExpenditure&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 40581000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#9003 The citation records this snapshot. The page link may show a newer release later.	−USD 43.47 million Calculation and evidence -2893000 − 40581000 USD Exact free cash flow: -43474000 USD 2007-01-01 – 2007-12-31: -2893000 USD · Inspect Operating Cash Flow · Source 2007-01-01 – 2007-12-31: 40581000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Abraxis BioScience, Inc. · 2007-12-31 Abraxis BioScience, Inc. (edgar:1409012) Free cash flow: -43474000 USD Concept: free-cash-flow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2893000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#8961 Input fundies:CapitalExpenditure: 40581000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#9003 The citation records this snapshot. The page link may show a newer release later.
2008 2008-01-01 – 2008-12-31	−USD 276.77 million Exact value Exact value: -276771000 USD 2008-01-01 – 2008-12-31: -276771000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Abraxis BioScience, Inc. · 2008-12-31 Abraxis BioScience, Inc. (edgar:1409012) Net Income: -276771000 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3ANetIncome&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:NetIncome: -276771000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#6971 The citation records this snapshot. The page link may show a newer release later.	−USD 315.47 million Exact value Exact value: -315468000 USD 2008-01-01 – 2008-12-31: -315468000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Abraxis BioScience, Inc. · 2008-12-31 Abraxis BioScience, Inc. (edgar:1409012) Operating Cash Flow: -315468000 USD Concept: fundies:OperatingCashFlow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3AOperatingCashFlow&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -315468000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#8961 The citation records this snapshot. The page link may show a newer release later.	USD 43.73 million Exact value Exact value: 43729000 USD 2008-01-01 – 2008-12-31: 43729000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Abraxis BioScience, Inc. · 2008-12-31 Abraxis BioScience, Inc. (edgar:1409012) Capital Expenditure: 43729000 USD Concept: fundies:CapitalExpenditure Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3ACapitalExpenditure&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 43729000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#9003 The citation records this snapshot. The page link may show a newer release later.	−USD 359.2 million Calculation and evidence -315468000 − 43729000 USD Exact free cash flow: -359197000 USD 2008-01-01 – 2008-12-31: -315468000 USD · Inspect Operating Cash Flow · Source 2008-01-01 – 2008-12-31: 43729000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Abraxis BioScience, Inc. · 2008-12-31 Abraxis BioScience, Inc. (edgar:1409012) Free cash flow: -359197000 USD Concept: free-cash-flow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -315468000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#8961 Input fundies:CapitalExpenditure: 43729000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#9003 The citation records this snapshot. The page link may show a newer release later.
2009 2009-01-01 – 2009-12-31	−USD 103.12 million Exact value Exact value: -103116000 USD 2009-01-01 – 2009-12-31: -103116000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Abraxis BioScience, Inc. · 2009-12-31 Abraxis BioScience, Inc. (edgar:1409012) Net Income: -103116000 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3ANetIncome&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:NetIncome: -103116000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#6971 The citation records this snapshot. The page link may show a newer release later.	USD 4.49 million Exact value Exact value: 4488000 USD 2009-01-01 – 2009-12-31: 4488000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Abraxis BioScience, Inc. · 2009-12-31 Abraxis BioScience, Inc. (edgar:1409012) Operating Cash Flow: 4488000 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3AOperatingCashFlow&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 4488000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#8961 The citation records this snapshot. The page link may show a newer release later.	USD 94.47 million Exact value Exact value: 94473000 USD 2009-01-01 – 2009-12-31: 94473000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Abraxis BioScience, Inc. · 2009-12-31 Abraxis BioScience, Inc. (edgar:1409012) Capital Expenditure: 94473000 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012/explain?concept=fundies%3ACapitalExpenditure&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 94473000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#9003 The citation records this snapshot. The page link may show a newer release later.	−USD 89.99 million Calculation and evidence 4488000 − 94473000 USD Exact free cash flow: -89985000 USD 2009-01-01 – 2009-12-31: 4488000 USD · Inspect Operating Cash Flow · Source 2009-01-01 – 2009-12-31: 94473000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Abraxis BioScience, Inc. · 2009-12-31 Abraxis BioScience, Inc. (edgar:1409012) Free cash flow: -89985000 USD Concept: free-cash-flow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-08T23:24:19Z Snapshot: ce80aa55bbf660ee8845860e1aac9e805517368669f137bafde9b6d05c2af763 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409012?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 4488000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#8961 Input fundies:CapitalExpenditure: 94473000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409012/0001193125-10-055402.txt#9003 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

17 filings · 0 latest values · 0 originally reported values

Dataset published 2026-11-08. Source filing dates and reporting periods are shown separately.

Identifiers: 0001409012, 1409012, edgar:1409012

Also known as Abraxis Biosciences, Inc., New Abraxis, Inc.

Abraxis BioScience, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2009 2009-01-01 – 2009-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation